(Q36766052)

16 August 2017

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

1 reference

V Roulstone

1

1 reference

16 August 2017

K Twigger

2

1 reference

16 August 2017

S Zaidi

3

1 reference

16 August 2017

T Pencavel

4

1 reference

16 August 2017

J N Kyula

5

1 reference

16 August 2017

C White

6

1 reference

16 August 2017

M McLaughlin

7

1 reference

16 August 2017

R Seth

8

1 reference

16 August 2017

E M Karapanagiotou

9

1 reference

16 August 2017

D Mansfield

10

1 reference

16 August 2017

M Coffey

11

1 reference

16 August 2017

G Nuovo

12

1 reference

16 August 2017

R G Vile

13

1 reference

16 August 2017

H S Pandha

14

1 reference

16 August 2017

A A Melcher

15

1 reference

16 August 2017

K J Harrington

16

1 reference

16 August 2017

16 August 2012

1 reference

16 August 2017

1 reference

16 August 2017

20

1 reference

16 August 2017

5

1 reference

16 August 2017

521-528

1 reference

describes a project that uses

16 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4821071/fullTextXML

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1038/gt.2012.68

0 references

cites work

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Reovirus therapy of tumors with activated Ras pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Reovirus infections in human volunteers.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821071

Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FGT.2012.68

A study of human reovirus IgG and IgA antibodies by ELISA and western blot

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22895509

12 December 2020

inferred from PubMed ID database lookup

Reovirus therapy in cancer: has the orphan virus found a home?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22895509

12 December 2020

inferred from PubMed ID database lookup

Results of a national survey of radiotherapy planning and delivery in the UK in 2007

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FGT.2012.68

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/GT.2012.68

1 reference

release_xq7k5v5kpnbqppcr4cf4u43g4u

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xq7k5v5kpnbqppcr4cf4u43g4u

24 November 2022

mapped directly with Wikidata item

1 reference

16 August 2017

1 reference